Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Granules IndiaBOM:532482 -0.73%81 Days Inventory is 300.63 as of Jun. 2026, which is 90% above its 10-year median of 158.02. GuruFocus rates BOM:532482 with a GF Score™ of 81/100 and a GF Value™ of ₹639.59 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 922 Drug Manufacturers companies, Granules India ranks worse than 81.78% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Granules India's Average Total Inventories for the
three
months ended in Jun. 2026 was ₹16,730 Mil. Granules India's Cost of Goods Sold for the
three
months ended in Jun. 2026 was ₹5,078 Mil.
Hence, Granules India's Days Inventory for the
three
months ended in Jun. 2026 was 300.63.
The historical rank and industry rank for Granules India's Days Inventory or its related term are showing as below:
BOM:532482'
s Days Inventory Range Over the Past 10 Years
Min: 94.3 Med: 158.02 Max: 279.81
Current: 279.81
During the past 13 years, Granules India's highest Days Inventory was 279.81. The lowest was 94.30. And the median was 158.02.
BOM:532482's Days Inventory is ranked worse than 81.78% of 922
companies
in the Drug Manufacturers industry
Industry Median: 165.005
vs BOM:532482: 279.81
Granules India's Days Inventory
increased
from Jun. 2025 (288.27) to Jun. 2026 (300.63).
It might indicate that Granules India's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Granules India's Inventory Turnover for the
three
months ended in Jun. 2026 was 0.30.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Granules India's Inventory-to-Revenue for the
three
months ended in Jun. 2026 was 1.14.
Granules India (BOM:532482) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Granules India's Inventory Turnover for the
three
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Granules India's Inventory to Revenue for the
three
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Granules India Days Inventory Related Terms
Granules India Days Inventory Historical Data
* Premium members only.
The historical data trend for Granules India's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Granules India's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Granules India Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Granules India's Days Inventory distribution charts can be found below:
* The bar in red indicates where Granules India's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Granules India (BOM:532482) has a Days Inventory of 300.63 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Granules India and its competitors. This is 90% above median its historical median of 158.02. Over the past decade, Granules India's Days Inventory has ranged from 94.30 to 279.81. According to the industry distribution chart, Granules India ranks #754 out of 922 companies in the Drug Manufacturers industry, placing it in the top 81.8%.
Is Granules India's Days Inventory too high?
Granules India's current Days Inventory of 300.63 is 90% above median its 10-year median of 158.02. Over the past 10 years, this metric has ranged from a low of 94.30 to a high of 279.81. The Drug Manufacturers industry median Days Inventory is 165.01. Granules India's value of 300.63 is 82.2% above this industry median. Based on the distribution chart, Granules India ranks #754 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Granules India has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Granules India's Days Inventory compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Granules India ranks #754 out of 922 companies for Days Inventory. This places Granules India in the lower half of its industry. The industry median Days Inventory is 165.01. Granules India's value of 300.63 is 82.2% above this benchmark. Historically, Granules India's own Days Inventory has ranged from 94.30 to 279.81 over the past decade. While the company's 10-year median is 158.02 vs. the industry median of 165.01, Granules India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 165.01, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Granules India's current Days Inventory of 300.63 is 82.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Granules India and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 165.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Granules India's current Days Inventory is 300.63, which is 90% above median its own 10-year median of 158.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Granules India stock overvalued right now?
Based on GuruFocus' analysis, Granules India (BOM:532482) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹639.59, compared to a current price of ₹838.20 — trading 31.1% above its estimated fair value. The current Days Inventory is 300.63, which is 90% above median its 10-year median of 158.02 and 82.2% above the Drug Manufacturers industry median of 165.01. Granules India's overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Granules India (BOM:532482), the current Days Inventory is 300.63 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Granules India (BOM:532482) Overvalued in 2026?
Based on GuruFocus' analysis, Granules India stock appears to be overvalued.
The current stock price of ₹838.20 is trading 31.1% above its estimated GF Value™ of ₹639.59.
GuruFocus considers Granules India to be Significantly Overvalued.
Key valuation signals for BOM:532482:
Days Inventory: 300.63 (90% above median its 10-year median of 158.02)
GF Value™: ₹639.59 vs. price of ₹838.20 (31.1% above fair value)
Industry Position: 82.2% above the Drug Manufacturers median (#754 of 922)
No single metric tells the full story. See the BOM:532482 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Granules India Ltd is an India-based pharmaceutical company. The company manufactures active pharmaceutical ingredients, pharmaceutical formulation intermediates, and finished dosages. It has one segment Pharmaceutical products including ingredients and intermediaries. Its primary geographic markets are North America, Latin America, Europe, India, and the Rest of the World. The company generates a majority of its revenue from its business outside India.
81GF Score
Get the complete analysis for BOM:532482
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532482 has been successfully added to your 
